Patients spoke at a hearing in Washington in support of using Avastin for breast cancer, but federal regulators voted against using the drug for that purpose. The Food and Drug Administration\'s Oncologic Drugs Advisory Committee voted 12-1 last July to strip Avastin\'s approval as a breast cancer drug because the drug was not improving the survival rate for women with breast cancer while at the same time exposing them to dangerous side effects. At the hearing Wednesday, Genentech, a subsidiary of Roche, defended its research, saying certain patients respond especially well and side effects, while potentially serious, are no worse than with other breast cancer drugs, CNN reported. An expert said said for some women there are no better treatments available than Avastin, an approved breast cancer drug in Europe. The drug will remain on the market for other cancer treatments, but if the FDA follows the panel\'s recommendation insurance companies wouldn\'t cover it for breast cancer patients and the cost of the drug about $100,000 a year may be too high for them to pay for themselves, CNN said.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delaysMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor